Navigation Links
Chembio Provides Business Update
Date:1/3/2012

MEDFORD, N.Y., Jan. 3, 2012 /PRNewswire/ -- Chembio Diagnostics, Inc. (OTC.PK: CEMI and OTC.QB: CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, is providing this update regarding 2011 developments in the fourth quarter and an updated outlook for 2012.

 

  1. 2011 Revenues - Chembio once again achieved record revenues based on record product shipments during the second half of the year.  Audited financial results will be reported in March. 
  2. 2012 Outlook - We are starting off 2012 with a very strong backlog.  We have received the 2012 forecasted demand from the Oswaldo Cruz Foundation (FIOCRUZ) of Brazil. Based on that, combined with conservative assumptions for the rest of our business, we anticipate that our 2012 revenues will  increase significantly over those of 2011.
  3. DPP® HIV Clinical Study - We are encouraged by the results we have had, as they continue to support approval on oral fluid, finger-stick whole blood, venous whole blood, serum and plasma samples. However, we are about three months behind our previously anticipated schedule.  This is primarily due to delays that occurred because our final clinical trial sites did not receive their Internal Review Board (IRB) approvals when they were expected and because of the slower pace of recruitment of known positive pediatric patients. As a result, the recruitment and testing of approximately 200 patients in our 3,000-patient study did not occur by year-end as we had previously anticipated.  Instead, we now expect the clinical trials to be completed by the end of the first quarter of 2012. Therefore our anticipated timeline, based on this delay, is now that we can submit our Module III to the FDA during the second quarter and, based on statutory FDA timetables, we could get FDA approval sometime between the fall of 2012 and early 2013.  W
    '/>"/>

SOURCE Chembio Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Chembio Reports 3rd Quarter 2011 Results
2. Chembio to Host Conference Call to Discuss 3rd Quarter 2011 Financial Results
3. Chembio Diagnostics CFO Richard J. Larkin Among the Recipients of "2011 CFO of the Year" Award from Long Island Business News
4. Medical Alarm Concepts Releases Initial Cut of New Television Commercial Scheduled for January Airing - Provides Investor Update
5. CareFusion Provides Update on Previously Announced Ventilator Recall
6. Generex Provides Update on Bloomberg TV Breast Cancer Vaccine Segment
7. PDL BioPharma Provides Fourth Quarter 2011 Revenue Guidance of $72 Million
8. Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting
9. Big Blue Test 2011 Provides Life-Saving Insulin and Supplies to More Than 8,000 People in Need
10. Lilly Provides Additional Funding to Infectious Disease Research Institute to Identify New Tuberculosis Therapies
11. Linking EudraCT and ClinicalTrials.gov Records Provides Huge Benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , October 31, 2014 ... clinical-stage pharmaceutical company focused on the development of ... will host a conference call to discuss the ... of ORMD-0801, the company,s proprietary oral insulin capsules, ... 3, 2014 at 10:00 a.m. Eastern time. ...
(Date:10/31/2014)... October 31, 2014 Today, Analysts ... CELG ), Bristol-Myers Squibb Co. (NYSE: ... UNH ), Sanofi SA (NYSE: SNY ) ... these notes ahead of publication. To reserve complementary membership, ... ,-- ,Celgene Corporation Research Reports ,On October 23, 2014, ...
(Date:10/31/2014)... CHICAGO , Oct. 31, 2014  Zacks.com announces the list ... Equity Research analysts discuss the latest news and events impacting stocks ... Amgen (Nasdaq: AMGN - Free Report ), Celgene ... (Nasdaq: BIIB - Free Report ), Market Vectors ... and SPDR S&P Biotech ETF (AMEX: XBI - ...
Breaking Medicine Technology:Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7
... and Effective in Patients ... Open-Heart Surgery, WASHINGTON, Sept. 1 Data announced ... very complex coronary,artery disease can safely choose to be ... says The Society for,Cardiovascular Angiography and Interventions (SCAI). The ...
... recent,concern that suicide may be a complication of ... Administration (FDA) approved oral,drug that has been prescribed ... of,asthma and seasonal allergy symptoms. An independent study ... evidence of depression or suicide,linked to montelukast., ...
Cached Medicine Technology:SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 2SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 3American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast 2American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast 3
(Date:10/31/2014)... (PRWEB) October 31, 2014 Daily Gossip writes ... is actually described as the fastest fat loss program ever ... less than a month. , There is no wonder after ... eBook of all time. The new nutrition and workout fat ... and fitness expert. , According to the author of ...
(Date:10/31/2014)... Activz Whole-Food Nutrition is ... line offering natural silver healing support† in liquid supplements, ... silver has been used to support natural healing, and ... the most advanced version available. This latest formula, backed ... that supports the existing healing mechanisms in the human ...
(Date:10/31/2014)... terms of duration of treatment and cost, patients ... accelerated partial breast irradiation (APBI) with proton therapy ... research from The University of Texas MD Anderson ... cost analysis study based on typical patient characteristics, ... charges for eight different types of partial and ...
(Date:10/31/2014)... The Suspension Revolution review published by Daily Gossip ... Dan Long, a suspension training specialist. , Long ... life coach. The author of this program claims that ... impossible , The Suspension Revolution review reveals that this ... efficiency when it comes to burning fat, building muscles, ...
(Date:10/31/2014)... York, NY (PRWEB) October 31, 2014 ... one of the most remarkable gifts of life — ... platform for matching extraordinary surrogate mothers and donors with ... about individuals in unforeseen circumstances. , It’s a collective ... donors, surrogacy agencies, surrogacy lawyers, and fertility clinics that ...
Breaking Medicine News(10 mins):Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3
... WASHINGTON, May 12 Speaker Nancy Pelosi released ... the Social Security and Medicare Trustees, which was released ... of the Social Security and Medicare trust funds. ... left behind a record of recession, deficits and debt, ...
... In a meeting today with President Obama and ... Inc. (REI) drew praise for their innovative employee health ... Association (RILA).Following the meeting, President Obama referred to the ... and Safeway President and CEO Steven Burd, as "some ...
... to hear world voices, especially voices from Africa, about ... , - Dr. Paul Zeitz, GAA executive directorWASHINGTON, May ... than 12,000 health advocates and organizations around the world, ... Zeitz called for a worldwide response to fix ...
... PARS) today reported results for the first quarter ended March ... million, or $0.14 per share, for the first quarter 2009 ... per share, in the first quarter 2008. Cash and short-term ... in net loss for the first quarter 2009 vs. first ...
... Nektar Therapeutics (Nasdaq: NKTR ) is scheduled ... Care Conference in Boston at the Boston InterContinental Hotel on ... will be accessible via a Webcast through a link posted ... website: http://www.nektar.com . This ...
... BurrellesLuce is sponsoring a multifaceted look at "Advanced PR Strategies," one of ... Summit, to take place Sunday, May 17, through Tuesday, May 19, in ... ... BurrellesLuce is sponsoring a multifaceted look at "Advanced PR Strategies," ...
Cached Medicine News:Health News:President Obama Praises Retailers as Part of the Health Care Solution 2Health News:GAA Calls For a Worldwide Response to President Obama's Global Health Budget Shortfalls 2Health News:Pharmos Corporation Reports 2009 First Quarter Results 2Health News:Pharmos Corporation Reports 2009 First Quarter Results 3Health News:Pharmos Corporation Reports 2009 First Quarter Results 4Health News:Pharmos Corporation Reports 2009 First Quarter Results 5Health News:BurrellesLuce Sponsoring Track on 'Advanced PR Strategies' At Annual Industry Summit to Be Held May 17-19 in New York 2Health News:BurrellesLuce Sponsoring Track on 'Advanced PR Strategies' At Annual Industry Summit to Be Held May 17-19 in New York 3
Magniclear is the first presbyopic lens to combine the clear distance optics of a spherical lens, the intermediate visual performance of a multifocal and the predictably crisp, near power of a bifoca...
... is a simultaneous vision lens ... Through a series of front ... LifeStyle Gp delivers up to ... its multi-aspheric center-distance design works ...
Gendron ophthalmic eye surgery stretcher....
... surgical stretcher. M-701 Stretcher has a ... to 32 in., measured with a ... a high range, 28 in. to ... pad can be supplied optionally. Vinyl ...
Medicine Products: